Login to Your Account



Quest for the Home Run Goes On

Merck: Stealing a 'BACE' After Lilly Ends Alzheimer's Phase II?

By Randy Osborne
Staff Writer

Wednesday, June 19, 2013
Eli Lilly and Co.'s decision to stop its Phase II study with LY2886721, a beta secretase (BACE) inhibitor as a potential once-daily treatment for slowing Alzheimer's disease (AD), was "sad news, obviously," said Decision Resources analyst Georgiana Kuhlmann.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription